{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:13:09Z","timestamp":1766268789970},"reference-count":40,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.5551\/jat.49494","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T22:04:47Z","timestamp":1567548287000},"page":"353-362","source":"Crossref","is-referenced-by-count":15,"title":["Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase"],"prefix":"10.5551","volume":"27","author":[{"given":"Satoko","family":"Sakurai","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yasumoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion Medicine, Nara Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Kinki Block Blood Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) George JN and Nester CM: Syndromes of thrombotic microangiopathy. N Engl J Med, 2014; 371: 654-666","DOI":"10.1056\/NEJMra1312353"},{"key":"2","unstructured":"2) Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S and Smith RJ: Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int, 2017; 91: 539-551"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H and Kagami S: Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol, 2016; 20: 536-543","DOI":"10.1007\/s10157-016-1276-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P and Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int, 1998; 53: 836-844","DOI":"10.1111\/j.1523-1755.1998.00824.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P and Smith RJ: Atypical aHUS: State of the art. Mol Immunol, 2015; 67: 31-42","DOI":"10.1016\/j.molimm.2015.03.246"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH and Fremeaux-Bacchi V: Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol, 2005; 16: 555-563","DOI":"10.1681\/ASN.2004050380"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Jokiranta TS: HUS and atypical HUS. Blood, 2017; 129: 2847-2856","DOI":"10.1182\/blood-2016-11-709865"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE and Lambris JD: Complement and coagulation: strangers or partners in crime? Trends Immunol, 2007; 28: 184-192","DOI":"10.1016\/j.it.2007.02.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Oikonomopoulou K, Ricklin D, Ward PA and Lambris JD: Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol, 2012; 34: 151-165","DOI":"10.1007\/s00281-011-0280-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Conway EM: Reincarnation of ancient links between coagulation and complement. J Thromb Haemost, 2015; 13 Suppl 1: S121-132","DOI":"10.1111\/jth.12950"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL and Faas SJ: Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood, 2015; 125: 3253-3262","DOI":"10.1182\/blood-2014-09-600411"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, Ohishi K, Maruyama K, Imai H, Mizutani H and Nobori T: Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res, 2012; 129: 598-602","DOI":"10.1016\/j.thromres.2011.10.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T and Nangaku M: Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol, 2018; 22: 1088-1099","DOI":"10.1007\/s10157-018-1549-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH and Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010; 5: 1844-1859","DOI":"10.2215\/CJN.02210310"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yoshida Y, Kato H, Ikeda Y and Nangaku M: Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb, 2019; 26: 99-110","DOI":"10.5551\/jat.RV17026"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Taylor FB, Jr., Toh CH, Hoots WK, Wada H and Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost, 2001; 86: 1327-1330","DOI":"10.1055\/s-0037-1616068"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Levi M, de Jonge E, van der Poll T and ten Cate H: Disseminated intravascular coagulation. Thromb Haemost, 1999; 82: 695-705","DOI":"10.1055\/s-0037-1615899"},{"key":"18","unstructured":"18) Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M and Rodriguez de Cordoba S: Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol, 2016; 14 Suppl 11: 2-15"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Daves M, Giacomuzzi K, Tagnin E, Jani E, Adcock Funk DM, Favaloro EJ and Lippi G: Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma. Blood Coagul Fibrinolysis, 2014; 25: 292-295","DOI":"10.1097\/MBC.0000000000000026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, Madoiwa S and Wada H: Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J, 2016; 14: 42","DOI":"10.1186\/s12959-016-0117-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Suzuki A, Ebinuma H, Matsuo M, Miyazaki O and Yago H: The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res, 2007; 121: 377-385","DOI":"10.1016\/j.thromres.2007.05.008"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kobayashi N, Maekawa T, Takada M, Tanaka H and Gonmori H: Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol, 1983; 265-275","DOI":"10.1159\/000408467"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cataland SR, Holers VM, Geyer S, Yang S and Wu HM: Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood, 2014; 123: 3733-3738","DOI":"10.1182\/blood-2013-12-547067"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Zhang T, Chen H, Liang S, Chen D, Zheng C, Zeng C, Zhang H and Liu Z: A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study. PLoS One, 2014; 9: e111992","DOI":"10.1371\/journal.pone.0111992"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Cavero T, Rabasco C, Lopez A, Roman E, Avila A, Sevillano A, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, Garcia A, Mendizabal S, Gavela E, Macia M, Quintana LF, Maria Romera A, Borrego J, Arjona E, Espinosa M, Portoles J, Gracia-Iguacel C, Gonzalez-Parra E, Aljama P, Morales E, Cao M, Rodriguez de Cordoba S and Praga M: Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant, 2017; 32: 466-474","DOI":"10.1093\/ndt\/gfw453"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Moake JL, Turner NA, Stathopoulos NA, Nolasco LH and Hellums JD: Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest, 1986; 78: 1456-1461","DOI":"10.1172\/JCI112736"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Galbusera M, Benigni A, Paris S, Ruggenenti P, Zoja C, Rossi C and Remuzzi G: Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J Am Soc Nephrol, 1999; 10: 1234-1241","DOI":"10.1681\/ASN.V1061234"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kushimoto S, Wada H, Kawasugi K, Okamoto K, Uchiyama T, Seki Y, Hatada T, Imai H and Nobori T: Increased ratio of soluble fibrin formation\/thrombin generation in patients with DIC. Clin Appl Thromb Hemost, 2012; 18: 628-632","DOI":"10.1177\/1076029612451648"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, Uchida A and Nobori T: Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost, 2006; 4: 1253-1258","DOI":"10.1111\/j.1538-7836.2006.01942.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD and Huber-Lang M: Molecular intercommunication between the complement and coagulation systems. J Immunol, 2010; 185: 5628-5636","DOI":"10.4049\/jimmunol.0903678"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Martel C, Cointe S, Maurice P, Matar S, Ghitescu M, Theroux P and Bonnefoy A: Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One, 2011; 6: e18812","DOI":"10.1371\/journal.pone.0018812"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Polley MJ and Nachman RL: Human platelet activation by C3a and C3a des-arg. J Exp Med, 1983; 158: 603-615","DOI":"10.1084\/jem.158.2.603"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Wiedmer T and Sims PJ: Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem, 1985; 260: 8014-8019","DOI":"10.1016\/S0021-9258(17)39556-X"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35) Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H and Niho Y: C5a induces tissue factor activity on endothelial cells. Thromb Haemost, 1997; 77: 394-398","DOI":"10.1055\/s-0038-1655974"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36) Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A and Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med, 1997; 185: 1619-1627","DOI":"10.1084\/jem.185.9.1619"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J and Scully M: Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest, 2017; 152: 424-434","DOI":"10.1016\/j.chest.2017.03.055"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Kurosawa S and Stearns-Kurosawa DJ: Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care, 2014; 2: 65","DOI":"10.1186\/s40560-014-0061-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39) Abe T, Sasaki A, Ueda T, Miyakawa Y and Ochiai H: Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore), 2017; 96: e6056","DOI":"10.1097\/MD.0000000000006056"},{"key":"39","unstructured":"40) Department of Clinical Laboratory, The University of Tokyo Hospital [http:\/\/lab-tky.umin.jp\/patient\/ketueki.pdf] Accessed 7 June 2019"},{"key":"40","unstructured":"41) National Center for Child Health and Development [https:\/\/sogo-igaku.co.jp\/lec_in_ped\/0302.html] Accessed 7 June 2019"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/4\/27_49494\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T10:29:22Z","timestamp":1664274562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/27\/4\/27_49494\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.49494","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}